{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:14:37Z","timestamp":1756682077123},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objectives<\/jats:title>\n                <jats:p>Few studies have reported which inhaled combination therapy, either bronchodilators and\/or inhaled corticosteroids (ICSs), is beneficial in patients with bronchiectasis and airflow obstruction. Our study compared the efficacy and safety among different inhaled combination therapies in patients with bronchiectasis and airflow obstruction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our retrospective study analyzed the patients with forced expiratory volume in 1\u00a0s (FEV<jats:sub>1<\/jats:sub>)\/forced vital capacity\u2009&lt;\u20090.7 and radiologically confirmed bronchiectasis in chest computed tomography between January 2005 and December 2021. The eligible patients underwent baseline and follow-up spirometric assessments. The primary endpoint was the development of a moderate-to-severe exacerbation. The secondary endpoints were the change in the annual FEV<jats:sub>1<\/jats:sub> and the adverse events. Subgroup analyses were performed according to the blood eosinophil count (BEC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 179 patients, the ICS\/long-acting beta-agonist (LABA)\/long-acting muscarinic antagonist (LAMA), ICS\/LABA, and LABA\/LAMA groups were comprised of 58 (32.4%), 52 (29.1%), and 69 (38.5%) patients, respectively. ICS\/LABA\/LAMA group had a higher severity of bronchiectasis and airflow obstruction, than other groups. In the subgroup with BEC\u2009\u2265\u2009300\/uL, the risk of moderate-to-severe exacerbation was lower in the ICS\/LABA\/LAMA group (adjusted HR\u2009=\u20090.137 [95% CI\u2009=\u20090.034\u20130.553]) and the ICS\/LABA group (adjusted HR\u2009=\u20090.196 [95% CI\u2009=\u20090.045\u20130.861]) compared with the LABA\/LAMA group. The annual FEV<jats:sub>1<\/jats:sub> decline rate was significantly worsened in the ICS\/LABA group compared to the LABA\/LAMA group (adjusted \u03b2-coefficient=-197 [95% CI=-307\u2013-87]) in the subgroup with BEC\u2009&lt;\u2009200\/uL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In patients with bronchiectasis and airflow obstruction, the use of ICS\/LABA\/LAMA and ICS\/LABA demonstrated a reduced risk of exacerbation compared to LABA\/LAMA therapy in those with BEC\u2009\u2265\u2009300\/uL. Conversely, for those with BEC\u2009&lt;\u2009200\/uL, the use of ICS\/LABA was associated with an accelerated decline in FEV<jats:sub>1<\/jats:sub> in comparison to LABA\/LAMA therapy. Further assessment of BEC is necessary as a potential biomarker for the use of ICS in patients with bronchiectasis and airflow obstruction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-024-02867-4","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T11:02:17Z","timestamp":1706007737000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction"],"prefix":"10.1186","volume":"24","author":[{"given":"Hyo Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Young","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deog Kyeom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"issue":"5","key":"2867_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/SMJ.0b013e31802fa16f","volume":"100","author":"IK Oguzulgen","year":"2007","unstructured":"Oguzulgen IK, Kervan F, Ozis T, Turktas H. The impact of bronchiectasis in clinical presentation of asthma. South Med J. 2007;100(5):468\u201371.","journal-title":"South Med J"},{"key":"2867_CR2","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2147\/COPD.S132961","volume":"12","author":"MA Martinez-Garcia","year":"2017","unstructured":"Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017;12:1401\u201311.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"2867_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1183\/09031936.00170014","volume":"45","author":"JR Hurst","year":"2015","unstructured":"Hurst JR, Elborn JS, Soyza AD. COPD\u2013bronchiectasis overlap syndrome. Eur Respir J. 2015;45(2):310\u20133.","journal-title":"Eur Respir J"},{"issue":"4","key":"2867_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1164\/rccm.200305-648OC","volume":"170","author":"IS Patel","year":"2004","unstructured":"Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2867_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1164\/rccm.201208-1518OC","volume":"187","author":"MA Mart\u00ednez-Garc\u00eda","year":"2013","unstructured":"Mart\u00ednez-Garc\u00eda MA, de la Rosa Carrillo D, Soler-Catalu\u00f1a JJ, Donat-Sanz Y, Serra PC, Lerma MA, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823\u201331.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"2867_CR6","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"MC Pasteur","year":"2010","unstructured":"Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1\u201358.","journal-title":"Thorax"},{"issue":"2","key":"2867_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1378\/chest.11-0180","volume":"141","author":"M Mart\u00ednez-Garc\u00eda","year":"2012","unstructured":"Mart\u00ednez-Garc\u00eda M, Soler-Catalu\u00f1a JJ, Catal\u00e1n-Serra P, Rom\u00e1n-S\u00e1nchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141(2):461\u20138.","journal-title":"Chest"},{"issue":"1","key":"2867_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.21037\/jtd-20-1282","volume":"13","author":"SY Lee","year":"2021","unstructured":"Lee SY, Lee JS, Lee SW, Oh YM. Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study. J Thorac Disease. 2021;13(1):169\u201377.","journal-title":"J Thorac Disease"},{"issue":"9596","key":"2867_CR9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"key":"2867_CR10","unstructured":"2022 Global Strategy for diagnosis, Management and Prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease."},{"key":"2867_CR11","doi-asserted-by":"crossref","unstructured":"D\u00edaz AA, Nardelli P, Wang W, San Jos\u00e9 Est\u00e9par R, Yen A, Kligerman S et al. Artificial Intelligence-based CT Assessment of Bronchiectasis: the COPDGene Study. Radiology. 2022:221109.","DOI":"10.1148\/radiol.221109"},{"issue":"1","key":"2867_CR12","first-page":"57","volume":"103","author":"JF Morris","year":"1971","unstructured":"Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis. 1971;103(1):57\u201367.","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"2867_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1183\/09031936.00086313","volume":"43","author":"PH Quanjer","year":"2014","unstructured":"Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J. 2014;43(2):505\u201312.","journal-title":"Eur Respir J"},{"issue":"5","key":"2867_CR14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1183\/09031936.05.00035205","volume":"26","author":"R Pellegrino","year":"2005","unstructured":"Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948\u201368.","journal-title":"Eur Respir J"},{"issue":"8","key":"2867_CR15","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70\u2013e88.","journal-title":"Am J Respir Crit Care Med"},{"key":"2867_CR16","doi-asserted-by":"crossref","unstructured":"Costa JC, Machado JN, Ferreira C, Gama J, Rodrigues C. The Bronchiectasis Severity Index and FACED score for assessment of the severity of bronchiectasis. Pulmonology. 2018.","DOI":"10.1016\/j.rppnen.2017.08.009"},{"issue":"18","key":"2867_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler Triple versus Dual Therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"key":"2867_CR18","doi-asserted-by":"crossref","unstructured":"Agust\u00ed A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med. 2023;207(7):819\u201337.","DOI":"10.1164\/rccm.202301-0106PP"},{"issue":"4","key":"2867_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s11096-012-9659-6","volume":"34","author":"R Hernando","year":"2012","unstructured":"Hernando R, Drobnic ME, Cruz MJ, Ferrer A, Su\u00f1\u00e9 P, Montoro JB, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm. 2012;34(4):644\u201350.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"2867_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0954-6111(06)80227-1","volume":"86","author":"JS Elborn","year":"1992","unstructured":"Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varghese G. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86(2):121\u20134.","journal-title":"Respir Med"},{"issue":"3","key":"2867_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/thx.2002.003236","volume":"60","author":"KW Tsang","year":"2005","unstructured":"Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60(3):239\u201343.","journal-title":"Thorax"},{"issue":"4","key":"2867_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/09031936.00003709","volume":"34","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34(4):843\u20139.","journal-title":"Eur Respir J"},{"issue":"4","key":"2867_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1164\/ajrccm.162.4.9906120","volume":"162","author":"MC PASTEUR","year":"2000","unstructured":"PASTEUR MC, HELLIWELL SM, HOUGHTON SJ, WEBB SC, FOWERAKER JE, COULDEN RA, et al. An investigation into causative factors in patients with Bronchiectasis. Am J Respir Crit Care Med. 2000;162(4):1277\u201384.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2867_CR24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1183\/09031936.06.00074605","volume":"28","author":"G Davies","year":"2006","unstructured":"Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of <\u2009em\u2009>\u2009Pseudomonas aeruginosa\u2009on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28(5):974\u20139.","journal-title":"Eur Respir J"},{"issue":"5","key":"2867_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1378\/chest.07-0490","volume":"132","author":"MA Mart\u00ednez-Garc\u00eda","year":"2007","unstructured":"Mart\u00ednez-Garc\u00eda MA, Soler-Catalu\u00f1a JJ, Perpi\u00f1\u00e1-Tordera M, Rom\u00e1n-S\u00e1nchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565\u201372.","journal-title":"Chest"},{"issue":"8","key":"2867_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.rmed.2007.03.009","volume":"101","author":"PT King","year":"2007","unstructured":"King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007;101(8):1633\u20138.","journal-title":"Respir Med"},{"issue":"6","key":"2867_CR27","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1378\/chest.114.6.1594","volume":"114","author":"PL Ho","year":"1998","unstructured":"Ho PL, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest. 1998;114(6):1594\u20138.","journal-title":"Chest"},{"issue":"1","key":"2867_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3346\/jkms.2004.19.1.62","volume":"19","author":"JH Lee","year":"2004","unstructured":"Lee JH, Kim YK, Kwag HJ, Chang JH. Relationships between high-resolution computed tomography, lung function and bacteriology in stable bronchiectasis. J Korean Med Sci. 2004;19(1):62\u20138.","journal-title":"J Korean Med Sci"},{"issue":"10","key":"2867_CR29","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1183\/09031936.94.07101746","volume":"7","author":"KW Tsang","year":"1994","unstructured":"Tsang KW, Rutman A, Tanaka E, Lund V, Dewar A, Cole PJ, et al. Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro. Eur Respir J. 1994;7(10):1746\u201353.","journal-title":"Eur Respir J"},{"issue":"5","key":"2867_CR30","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1183\/09031936.00119114","volume":"45","author":"JD Chalmers","year":"2015","unstructured":"Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446\u201362.","journal-title":"Eur Respir J"},{"key":"2867_CR31","first-page":"587","volume":"7","author":"R Jen","year":"2012","unstructured":"Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:587\u201395.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"2867_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1164\/ajrccm.158.3.9710090","volume":"158","author":"KW Tsang","year":"1998","unstructured":"Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158(3):723\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2867_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1378\/chest.117.2.420","volume":"117","author":"KW Tsang","year":"2000","unstructured":"Tsang KW, Chan K, Ho P, Zheng L, Ooi GC, Ho JC, et al. Sputum elastase in steady-state bronchiectasis. Chest. 2000;117(2):420\u20136.","journal-title":"Chest"},{"issue":"9","key":"2867_CR34","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.rmed.2005.12.002","volume":"100","author":"MA Mart\u00ednez-Garc\u00eda","year":"2006","unstructured":"Mart\u00ednez-Garc\u00eda MA, Perpi\u00f1\u00e1-Tordera M, Rom\u00e1n-S\u00e1nchez P, Soler-Catalu\u00f1a JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100(9):1623\u201332.","journal-title":"Respir Med"},{"issue":"6","key":"2867_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1164\/rccm.200408-1041OC","volume":"172","author":"OS Usmani","year":"2005","unstructured":"Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005;172(6):704\u201312.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2867_CR36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1183\/09031936.02.00283202","volume":"19","author":"PJ Barnes","year":"2002","unstructured":"Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19(1):182\u201391.","journal-title":"Eur Respir J"},{"issue":"19","key":"2867_CR37","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1016\/S0021-9258(19)76507-7","volume":"263","author":"S Collins","year":"1988","unstructured":"Collins S, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J Biol Chem. 1988;263(19):9067\u201370.","journal-title":"J Biol Chem"},{"issue":"1","key":"2867_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1172\/JCI118084","volume":"96","author":"JC Mak","year":"1995","unstructured":"Mak JC, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Investig. 1995;96(1):99\u2013106.","journal-title":"J Clin Investig"},{"issue":"1","key":"2867_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","volume":"21","author":"TH Harries","year":"2020","unstructured":"Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3.","journal-title":"Respir Res"},{"issue":"1","key":"2867_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"2867_CR41","first-page":"14","volume":"8","author":"WJ Guan","year":"2016","unstructured":"Guan WJ, Gao YH, Xu G, Li HM, Yuan JJ, Zheng JP, et al. Bronchodilator response in adults with bronchiectasis: correlation with clinical parameters and prognostic implications. J Thorac Disease. 2016;8(1):14\u201323.","journal-title":"J Thorac Disease"},{"key":"2867_CR42","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.2147\/COPD.S115581","volume":"11","author":"HJ Jeong","year":"2016","unstructured":"Jeong HJ, Lee H, Carriere KC, Kim JH, Han JH, Shin B, et al. Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline. Int J Chron Obstruct Pulmon Dis. 2016;11:2757\u201364.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2867_CR43","doi-asserted-by":"crossref","unstructured":"Jayaram L, Vandal AC, Chang C, Lewis C, Tong C, Tuffery C et al. Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial. Eur Respir J. 2021.","DOI":"10.1183\/13993003.02184-2021"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-02867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-02867-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-02867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:30:40Z","timestamp":1706106640000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-02867-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-02867-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors declare no conflicts of interest for the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosure"}},{"value":"Our study was conducted in accordance with the ethical guidance of the Declaration of Helsinki in 1975. The Institutional Review Board Committee of Seoul National University Seoul Metropolitan Government (SNU-SMG) Boramae Medical Center approved the study protocol and waived the requirement for informed consent from study subjects for access to the electronic medical records (IRB No. 10-2020-099).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"49"}}